also the shareholders equity is only 3.1 mill and with a loss next quarter, they'll be below the threshold for nasdaq listing and thus DELISTED.. MIka NEVER intended for any cash to go to shareholders.. he kept it for himself and his cronies.. only thing he'll deliver to you bagholders is a bankruptcy filing
CLRX will need to do another capital raise next quarter. They have less than two quarters of cash left if they really skim expenses, as they are burning about $1.2 million per quarter. I was only able to listen to part of the conference call, up to the point where Mika said revenue was challenging (only $64,000 in the quarter is not good). I will listen to the rest of the call and Q&A tonight and have some additional comments.
On an important note, CLRX did improve the Board and the management team significantly with their two recent additions. This is vital, as Mika certainly does not have a good track record given his poor performance running Tegal. He needs all the help he can get, and to his credit, CLRX added a COO with strong sector experience and a Board Member with an outstanding track record.
The operating leverage in the CLRX business remains large, given the $5 million annual cost to break-even, not including expansion costs for other business lines. The customer base continues to improve, and it is true, that we are in the early innings of genetic testing. However, in contrast to what Mika said, testing of non-Foundation Medicine companies is alive and well, and ramping. Quest Diagnostics, in particular, is beefing up its focus on this sector and companion diagnostics are being developed by biopharma. As Foundation Medicine is proving, and they do have the best end-to-end platform for tissue based tests, the information that is being garnered from the testing is changing cancer care. FYI, Biocept (NASDAQ: BIOC) is very well positioned for lipid based testing, which will be a huge area to complement tissue based tests as FMI indicated on their quarterly call. In any case, each of the genetic testing firms are dealing with their own reimbursement issues...but so far, reimbursement has been reasonable, with most genetic tests ranging from $2,500-$3,5000. CLRX is clearly not making much money per test. More later...
Well? Was I right? No PR's = no revenues = horrible results? KEEP IN MIND, the forward-looking statement disclaimers allow Mika to say whatever he wants! Like "near term quarter's expenses will be offset by the quarter's revenues"??? Oh really? Is everybody going to work for free next quarter? EQ
Without any PR news on revenues you assume revenues are going to be close to zero and then you don't need any earnings leak to know that the results will be horrible. He needs to get the share price under a buck and the delisting threat to justify another reverse spit on the share"holers" and everybody knows that now. More dilution coming up again. I think it is that simple. No surprise to me as I have posted earlier. EQ
Quest has signed up with Sloan Kettering to try to compete with FMI so this should, in theory, be a huge boost for CLRX business. There is so much value potential in what FMI is doing...it's extremely cheap...I suspect this industry will develop similar to medical electronic record keeping. I see a company like AthenaHealth partnering with FMI, and FMI partnering with BIOC to add blood-based testing results (not just tissue) into their database...ultimately, I see a lot of information tying into to the Medical Record. FMI is really a game-changer in how oncologists treat patients...nearly 30% changed their decision making based on FMI's info. That's staggering...and enormous savings. Soon, that type of data will be front-end in terms of preventive medicine. And, similar databases can be developed for non-cancer gene based disease.
How low can this go? As low as someone is willing to dig to bury a turd. Under a buck for sure within six months to threaten delisting, that's Mika's curtain call for yet ANOTHER reverse spit on the share"holers". Perfect timing with October right around the corner with a weak overall market to blame! Yup! Bear trap WAS set in the cage alright. Now you will not see it above $2 with the need for a reverse spit with new money coming in AGAIN! Will save any good news now and combine it with earnings (I should say the LOSS report) after the spit takes place. I predict a very quite period now with the share price drifting lower and lower. Of course, I have been all wrong over the years according to Mika so what do I know. Best not to listen to him (like the Wizard of Oz on the big screen) and just look at the facts and results. Finally, I think people are starting to realize that and the money pump is drying up on him. This last one was just a six month squirt! Go Tegal! Oh, that's right. That company does not exist anymore after going through what $120 million or so. Peanuts on Wall Street! They have plenty of money to waste. EQ
A terrific concept that FMI has been able to implement, resulting in a huge market cap of over $500 million versus our $4 million [with 1/2 of that in cash]. Can't understand why a Quest or some major lab wouldn't want this product to add to the services they provide. After all this time it is probably time to put the company up for sale and see what we can get. Without management being able to ramp up sales significantly, shareholders would have to look forward to more secondary offerings. Might surprise us what another company might pay for our product in a sale?
pretty low -- until these guys can prove to (or convince) the market that their business model can generate significant real revenues and cash flow... this is merely a "concept" stock at this point in time (albeit a good concept, but I think the best scenario based on the fact they will need more cash soon is to sell out to a 3rd party-- probably at not the greatest premium unfortunately for current shareholders)
Hey! Will the new people ever be able to sell for more than the $2 they just paid? Or did they set a bear trap while they were caged? I predict one chance coming up to get out over $2 with some PR hype. After that it's down under a buck and the NAS delisting threat (AGAIN!) to justify a reverse spit on the share"holers" to set up yet another secondary and Mika payday. They are so LUCKY to have such a LOYAL DEVOTED employee who would NEVER ever dream of LEAVING on his own like most people would have done by now. Like bubble gum on the bottom of a shoe he keeps telling the foot where to step! EQ
Dilution was much lower than I thought it would be. Pricing is where I expected given Aegis was the underwriter and they are not very good. Based on some other companies that I've followed, I've noticed they really don't do spot secondaries well at all...don't have the institutional footprint compared to better shops. I think Mika didn't want to give the house away and that's why you only saw 1 million shares offered, which adds another 9 months of cash to the balance sheet. Curious to know which institutions stepped up to buy shares...